Document 0130
 DOCN  M9650130
 TI    Alterations in the immune response of human immunodeficiency virus
       (HIV)-infected subjects treated with an HIV-specific protease inhibitor,
       ritonavir.
 DT    9605
 AU    Kelleher AD; Carr A; Zaunders J; Cooper DA; Centre for Immunology,
       HIV-Medicine Unit, St. Vincent's Hospital,; Sydney, Australia.
 SO    J Infect Dis. 1996 Feb;173(2):321-9. Unique Identifier : AIDSLINE
       MED/96162089
 AB    Effects of a human immunodeficiency virus (HIV) type 1 protease
       inhibitor, ritonavir, were evaluated in 21 patients enrolled in a phase
       I/II study. The magnitude and rates of CD4 and CD8 lymphocyte increase,
       changes in subsets of CD4 and CD8 lymphocytes, and proliferative
       responses to mitogen and antigens were analyzed. Significant increases
       were noted in CD4 and CD8 lymphocyte counts; numbers of CD4CD45RO
       lymphocytes increased significantly by week 1 of therapy. Increases in
       the CD4CD45RA subset were observed at week 4. Reductions in the
       percentage of CD4 and CD8 lymphocytes expressing CD38 were noted.
       Increases in proliferative responses to phytohemagglutinin were noted in
       6 of 7 patients and correlated with duration of virus load suppression.
       Increased responses to recall antigens and to HIV-specific proteins were
       observed. Treatment with ritonavir produced alterations in the immune
       system that included changes in T cell subset distribution and increases
       in CD4 and CD8 lymphocyte numbers and of lymphocyte function.
 DE    Antigens, CD45/IMMUNOLOGY  Antigens, Differentiation/IMMUNOLOGY
       Antiviral Agents/*THERAPEUTIC USE  CD4 Lymphocyte Count  CD4-CD8 Ratio
       CD4-Positive T-Lymphocytes/IMMUNOLOGY  CD8-Positive
       T-Lymphocytes/IMMUNOLOGY  Double-Blind Method  Human  HIV
       Infections/*DRUG THERAPY/*IMMUNOLOGY  HIV Protease/DRUG EFFECTS  HIV
       Protease Inhibitors/*THERAPEUTIC USE  *HIV-1  Immune System/DRUG EFFECTS
       Lymphocyte Transformation  Nucleosidases/IMMUNOLOGY  RNA, Viral/DRUG
       EFFECTS  Support, Non-U.S. Gov't  Thiazoles/*THERAPEUTIC USE
       Valine/*ANALOGS & DERIVATIVES/THERAPEUTIC USE  Viremia/DRUG
       THERAPY/GENETICS/IMMUNOLOGY  CLINICAL TRIAL  CLINICAL TRIAL, PHASE I
       CLINICAL TRIAL, PHASE II  JOURNAL ARTICLE  MULTICENTER STUDY  RANDOMIZED
       CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).